Cytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCM - Has The Bull Case Changed?

Simply Wall St.

Yesterday

Cytokinetics recently reported that its pivotal Phase 3 ACACIA-HCM trial of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy met both dual primary endpoints, with statistically ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/2663010206"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2663010206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2663010206?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-30 03:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2663010206","market":"us","top_or_hot":-1,"title":"Cytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCM - Has The Bull Case Changed?","media":"Simply Wall St.","content":"<div>\n<p>Cytokinetics recently reported that its pivotal Phase 3 ACACIA-HCM trial of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy met both dual primary endpoints, with statistically ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-is-down-62-after-positive-phase-3-aficamte\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCM - Has The Bull Case Changed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCM - Has The Bull Case Changed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-30 03:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-is-down-62-after-positive-phase-3-aficamte><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cytokinetics recently reported that its pivotal Phase 3 ACACIA-HCM trial of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy met both dual primary endpoints, with statistically ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-is-down-62-after-positive-phase-3-aficamte\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-is-down-62-after-positive-phase-3-aficamte","article_id":"2663010206","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cytk/cytokinetics/news/cytokinetics-cytk-is-down-62-after-positive-phase-3-aficamte","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2663010206","pubTimestamp":1788031289,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Cytokinetics recently reported that its pivotal Phase 3 ACACIA-HCM trial of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy met both dual primary endpoints, with statistically significant gains in patient-reported symptoms and exercise capacity presented at ESC 2026 and published in leading cardiology journals.\nThe company also disclosed additional ACACIA-HCM and MAPLE-HCM data showing structural and functional cardiac benefits plus a detailed safety and REMS framework,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","CYTK":"Cytokinetics"},"translate_title":"在非梗阻性HCM中，3期Aficamten数据呈阳性后，细胞动力学（CYTK）下降了6.2%——牛市病例改变了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":1.5},"content_text":"Cytokinetics recently reported that its pivotal Phase 3 ACACIA-HCM trial of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy met both dual primary endpoints, with statistically significant gains in patient-reported symptoms and exercise capacity presented at ESC 2026 and published in leading cardiology journals. The company also disclosed additional ACACIA-HCM and MAPLE-HCM data showing structural and functional cardiac benefits plus a detailed safety and REMS framework, underlining how aficamten could extend the existing MYQORZO franchise beyond obstructive HCM if regulators ultimately grant a label expansion. Next, we’ll examine how aficamten’s first-ever positive Phase 3 results in non-obstructive HCM may reshape Cytokinetics’ investment narrative. We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementCytokinetics Investment Narrative RecapTo own Cytokinetics here, you have to believe aficamten can evolve into a multi-indication HCM franchise while the company manages high cash burn and regulatory complexity. The ACACIA-HCM Phase 3 win in non-obstructive HCM sharpens the near term catalyst around the planned Q4 2026 supplemental FDA filing, but it does not remove key risks around REMS requirements, commercialization pace and the company’s continued operating losses. The primary ACACIA-HCM readout presented at ESC 2026 and published in The New England Journal of Medicine is the most relevant milestone. It confirms statistically significant improvements in both patient-reported symptoms and exercise capacity, reinforcing Cytokinetics’ plan to seek a label expansion for aficamten beyond obstructive HCM. How regulators interpret the safety data, including heart failure events during titration and hypertension signals, now sits at the center of the next regulatory and commercial catalysts. Yet investors should also weigh how tighter REMS burdens, payer gatekeeping and potential funding needs could materially affect Cytokinetics’ path from promising data to real-world returns... Read the full narrative on Cytokinetics (it's free!)Cytokinetics' narrative projects $1.0 billion revenue and $178.9 million earnings by 2029. This requires 114.3% yearly revenue growth and a $1,008.5 million earnings increase from -$829.6 million today.Uncover how Cytokinetics' forecasts yield a $107.80 fair value, a 50% upside to its current price.Exploring Other PerspectivesCYTK 1-Year Stock Price Chart Before this ACACIA-HCM result, the most bullish analysts were already assuming revenue could grow about 129.7% a year to roughly US$1.3 billion by 2029, so if you are using that more optimistic lens, this new data might either reinforce your view of rapid uptake in hard to treat HCM or prompt you to revisit just how much execution and regulatory risk you are comfortable underwriting.Explore 3 other fair value estimates on Cytokinetics - why the stock might be worth over 6x more than the current price!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Cytokinetics research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.Our free Cytokinetics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cytokinetics' overall financial health at a glance.No Opportunity In Cytokinetics?Opportunities like this don't last. These are today's most promising picks. Check them out now:Outshine the giants: these 18 early-stage AI stocks could fund your retirement.Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}